Navigation Links
Mass. General study finds potential ovarian cancer stem cells

Massachusetts General Hospital (MGH) researchers have identified potential ovarian cancer stem cells, which may be behind the difficulty of treating these tumors with standard chemotherapy. Understanding more about the stem-like characteristics of these cells could lead to new approaches to treating ovarian cancer, which kills more than 16,000 U.S. women annually and is their fifth most common cause of cancer death. The report will appear in the July 25 Proceeding of the National Academy of Sciences (PNAS) and has received early online release.

"We feel these stem-like cancer cells may be resistant to traditional chemotherapy and could be responsible for the ultimately fatal drug-resistant recurrence that is characteristic of ovarian cancer," says Paul Szotek, MD, of the MGH Pediatric Surgical Research Laboratories, first author of the PNAS report. "We believe this likely is the first time stem-like cells have been found in models of ovarian cancer and in cells associated with human ovarian cancer."

Several recent studies have identified tiny populations of tumor cells that appear to act like stem cells, driving the tumor's ability to grow and spread. If some of these specialized cells escaped destruction by chemotherapy or radiation, the tumor would be able to recur quickly, often in a form resistant to chemotherapy. Similar cancer stem cells have been previously identified in leukemia and breast cancer and in cell lines of central nervous system and gastrointestinal tumors.

Standard treatment for ovarian cancer ?surgical removal of all involved tissues followed by chemotherapy ?usually appears successful, but treatment-resistant tumors recur in the vast majority of patients, leading to a five-year survival rate of less than 30 percent. Those factors and other observations suggested that cancer stem cells may also be found with ovarian tumors, leading to the current study.

The MGH researchers first examined two mouse ovar ian cancer cell lines and identified cells with characteristics of the cancer stem cells found with other tumors. They then observed a small percentage of stem-like cells in human ovarian cancer lines and in cells taken from ascites fluid that had accumulated within the abdomen of several ovarian cancer patients. When mouse ovarian tumor stem-like cells were injected under the skin of mice, they led to the formation of new tumors much faster than did injections of regular tumor cells.

Although the potential ovarian cancer stem cells were less responsive than regular tumor cells to in vitro treatment with the chemotherapy drug doxorubicin, the stem-like cells remained sensitive to repeated treatment with Mullerian Inhibiting Substance (MIS). This protein, important in the normal development of sexual organs, has been studied for its potential to treat several reproductive tumors by Patricia Donahoe, MD, director of the MGH Pediatric Surgical Research Laboratories and senior author of the PNAS study, and David MacLaughlin, PhD, associate director of the labs and a study co-author.

"We feel that non-traditional, possibly innovative approaches will be required to eradicate these stem-like cancer cells and ultimately cure ovarian cancer. With its potential to maintain the ability to inhibit the proliferation of these cells, MIS may play a role in these new therapeutic approaches," Donahoe says. "We intend to keep searching for stem-like cells in patient tumor samples and to study their responsiveness to both chemotherapeutic agents and to novel agents specifically targeted to stem cell as individualized therapy of the future." Donahoe is the Marshall K. Bartlett Professor of Surgery at Harvard Medical School.


Source:Massachusetts General Hospital

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:

(Date:10/29/2015)...  Connected health pioneer, Joseph C. Kvedar , ... health and wellness, and the business opportunities that arise ... Internet of Healthy Things . Long before health ... Dr. Kvedar, vice president, Connected Health, Partners HealthCare, was ... care from the hospital or doctor,s office into the ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... announced that Google has adopted the Synaptics ® ... solutions to power its newest flagship smartphones, the Nexus ... --> --> ... to provide strategic collaboration in the joint development of ...
(Date:10/23/2015)... and GOLETA, California , October ... conference, BIOPAC and SensoMotoric Instruments (SMI) announce a mobile ... tracking data captured during interactive real-world tasks ... play integration of their established wearable solutions for eye ... synchronize gaze behavior captured with SMI Eye Tracking ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), ... has closed the sale of its global contrast media ... Euronext) in a transaction valued at approximately $270 million. ... a total of approximately 1,000 employees spread across the ... Louis area. This entire workforce and the ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> Accutest Research Laboratories, ... Contract Research Organization (CRO), has formed ... Cancer Center - Temple Health for ... ,     (Photo: ) , ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
(Date:11/25/2015)... Mass. , Nov. 25, 2015 Harvard ... biotechnology company developing bioengineered organ implants for life-threatening conditions, ... present at the LD Micro "Main Event" investor conference ... The presentation will be webcast live and posted for ... be available at the conference for one-on-one meetings on ...
Breaking Biology Technology: